Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JINS HoldingsJNDOF 82 3-Year EBITDA Growth Rate is 49.20% as of Feb. 2026, which is 222% above its 10-year median of 15.30. GuruFocus rates JNDOF with a GF Score™ of 82/100 and a GF Value™ of $28.04 (Significantly Overvalued). Among 692 Medical Devices & Instruments companies, JINS Holdings ranks better than 88.01% on this metric.
During the past 12 months, JINS Holdings's average EBITDA Per Share Growth Rate was 22.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 49.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 17.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 5.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of JINS Holdings was 185.10% per year. The lowest was -20.10% per year. And the median was 15.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
JINS Holdings 3-Year EBITDA Growth Rate Related Terms
JNDOF vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, JINS Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JINS Holdings 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, JINS Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where JINS Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 49.20% mean?
JINS Holdings (JNDOF) has a 3-Year EBITDA Growth Rate of 49.20% as of Feb. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for JINS Holdings and its competitors. This is 222% above median its historical median of 15.30. According to the industry distribution chart, JINS Holdings ranks #83 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 12%.
Is JINS Holdings' 3-Year EBITDA Growth Rate too high?
JINS Holdings' current 3-Year EBITDA Growth Rate of 49.20% is 222% above median its 10-year median of 15.30. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. JINS Holdings' value of 49.20% is 500% above this industry median. Based on the distribution chart, JINS Holdings ranks #83 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, JINS Holdings has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does JINS Holdings' 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, JINS Holdings ranks #83 out of 692 companies for 3-Year EBITDA Growth Rate. This places JINS Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. JINS Holdings' value of 49.20% is 500% above this benchmark. While the company's 10-year median is 15.30 vs. the industry median of 8.20, JINS Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JINS Holdings's current 3-Year EBITDA Growth Rate of 49.20% is 500% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for JINS Holdings and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JINS Holdings's current 3-Year EBITDA Growth Rate is 49.20%, which is 222% above median its own 10-year median of 15.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JINS Holdings stock overvalued right now?
Based on GuruFocus' analysis, JINS Holdings (JNDOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $28.04, compared to a current price of $38.43 — trading 37.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 49.20%, which is 222% above median its 10-year median of 15.30 and 500% above the Medical Devices & Instruments industry median of 8.20. JINS Holdings' overall GF Score™ is 82/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For JINS Holdings (JNDOF), the current 3-Year EBITDA Growth Rate is 49.20% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JINS Holdings (JNDOF) Overvalued in 2026?
Based on GuruFocus' analysis, JINS Holdings stock appears to be overvalued.
The current stock price of $38.43 is trading 37.1% above its estimated GF Value™ of $28.04.
GuruFocus considers JINS Holdings to be Significantly Overvalued.
Key valuation signals for JNDOF:
3-Year EBITDA Growth Rate: 49.20% (222% above median its 10-year median of 15.30)
GF Value™: $28.04 vs. price of $38.43 (37.1% above fair value)
Industry Position: 500% above the Medical Devices & Instruments median (#83 of 692)
No single metric tells the full story. See the JNDOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JINS Holdings Inc is an eyewear retailer that manufactures and sells private-label fashion eyeglasses and sunglasses. It offers prescription eyeglasses and nonprescription fashion or functional eyeglasses. Its inventory is on the shelves, and it charges flat rates with generally no additional charges or options for lens features. Jin has more than 300 stores in Japan as well as locations in China, Taiwan, and the United States. Stores are typically located in high-traffic areas such as shopping centers, malls, and train stations.
82GF Score
Get the complete analysis for JNDOF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JNDOF has been successfully added to your 
